Comparison of the frequency of bacterial and viral infections among children with community-acquired pneumonia hospitalized across distinct severity categories: a prospective cross-sectional study

Amanda C. Nascimento-Carvalho¹, Olli Ruuskanen² and Cristiana M. Nascimento-Carvalho³*
Background
Community-acquired pneumonia (CAP) continues to be a major cause of death among children aged under 5 years worldwide and almost all of these deaths occur in developing countries [1]. In the 1980s, it was established that most children dying from CAP in these regions had bacterial infection. Such assumption was based on the results of bacterial culture of lung aspirates from cases in these developing countries, as well as of lung aspiration studies and post-mortem studies from cases in developed countries in the pre-antimicrobial era [2, 3]. During the last decade, a wide range of studies have been conducted across different continents with the purpose of investigating the aetiology of childhood CAP [4]. Of note, while in the former set of studies only conventional bacteriological methods were employed, new molecular tests have been used in recent investigations, which consequently increased the yield of microbiological results [5, 6]. In this latter group, children with different categories of severity have been included, either with non-severe, severe, or very severe disease [4]. However, the comparison of the frequencies of different aetiologies among children with CAP in distinct severity categories in an original study is lacking in literature to-date.

In this context, we assessed whether there was difference in the frequency of bacterial and viral infections among children with CAP in distinct severity subgroups.

Methods
This was a prospective cross-sectional study conducted at the Federal University of Bahia Hospital, in Salvador, North-eastern Brazil, where community-dwelling children from the low income population were first seen at the hospital's Emergency Room. This is a public service. Data were prospectively collected from September 2003 to May 2005. CAP diagnosis was based on the report of respiratory complaints and fever or difficulty breathing plus the detection of pulmonary infiltrate or pleural effusion on the chest radiograph taken at the initial evaluation and read by the paediatrician on duty. For the purpose of this analysis, only children with tachypnoea or chest indrawing were included. Every child under 5-years-old hospitalized due to CAP diagnosis at the Emergency Room, based on the aforementioned criteria, was enrolled. Those with chronic lung disease except asthma, underlying comorbidities (cancer, organ dysfunction like cardiac, hepatic, respiratory or renal insufficiency), any other concurrent infections (for example, measles, chickenpox, tuberculosis, whooping cough, otitis, gastroenteritis, pyodermitis, meningitis), suspected or diagnosed immunodeficiency (including children born to an HIV-infected mother), or transferred from other health-care units were excluded. The applied exclusion criteria assured that only previously healthy children were enrolled and the clinical characteristics were exclusively attributable to the current CAP episode.

Upon hospital admission, demographic and clinical data and biological samples were collected by the research team, after receiving written informed consent by parents or legal guardians. Detailed interviews regarding the current illness, general medical history and thorough physical examinations were performed to complete a standardized questionnaire and assure eligibility. Data on clinical evolution and outcome were not collected because treatment may influence them. Therefore, the focus of this investigation was the severity presented by patients upon admission to hospital. Nasopharyngeal aspirates (NPA) collected through the nostrils were stored (−70 °C) until virologic tests were performed. Blood was collected for blood culture (BACTEC automatic system), buffy-coat (−70 °C) and serum (−20 °C) storage. Follow-up visits occurred between 2 and 4 weeks after enrolment when blood was also collected for serum storage (−20 °C). This procedure allowed the comparison of specific IgG titres as an investigational tool to detect several aetiologies. Everyone in the study had to have both NPA and paired serum samples collected to assure the same opportunity for investigation of all pathogens included in the panel.

Nineteen aetiological agents were investigated: 11 viruses and 8 bacteria. Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis infections were investigated by blood culture and by searching for specific IgG increase tested by an in-house enzyme immune assay (ELISA) in paired serum samples. For pneumococcal infections, IgG antibodies to pneumococcal pneumolysin and pneumococcal C-polysaccharide were used; a ≥2-fold or ≥3-fold increase, respectively, in antibody titres, between paired serum samples, was considered diagnostic [7].

For H. influenzae and M. catarrhalis infections, Ig (polyvalent) antibodies against whole bacterial cell antigens were measured and a ≥3-fold antibody increase between paired serum samples was considered diagnostic [7]. Pneumococcal infection was also sought by pneumolysin-polymerase chain reaction (PCR) performed in acute buffy-coat for the detection of pneumococcal DNA [8]. Staphylococcus aureus infection was investigated by blood culture. Mycoplasma pneumoniae infection was investigated by testing for specific IgM by using a commercial ELISA kit (Plateia, Bio-Rad, Marnes La Coquette, France) [9]. Chlamydia trachomatis IgG antibodies were measured by a commercial, solid-phase ELISA (Ani Labsystems Ltd., Vantaa, Finland). The laboratory diagnosis was based on signal to cut-off (S/CO) values, which were ≥1.4 S/CO [10]. An in-house micro-immunofluorescence (MIF) test was used to measure
IgG, IgA and IgM antibodies to *Chlamydophila pneumoniae* and *Simkania negevensis*, using purified, formalized elementary bodies of strains Kajaani 6 in *C. pneumoniae* and ATCC strain Z (ATCC, Catalog no. VR-1471) in *S. negevensis* tests. The diagnosis was based on a ≥4-fold increase in IgG or IgA antibodies between the paired serum samples or on the presence of IgM antibodies (a titre of ≥10) [11]. Rhinovirus, enterovirus, and human metapneumovirus were investigated by reverse transcriptase PCR in NPA. Parainfluenza virus 1, 2, 3, respiratory syncytial virus (RSV), influenza virus A and B, and adenovirus were investigated by viral antigen identification in the NPA by time-resolved fluoroimmunoassay with monoclonal antibodies; additionally, virus-specific serum antibody titres were determined in paired serum samples using an ELISA with an antigen-coated solid phase and horseradish peroxidase conjugated rabbit anti-human IgG; a ≥3-fold antibody titres increase was considered diagnostic [12]. Human bocavirus was investigated by quantitative PCR of NPA and serum, IgG increase determination in paired serum samples and searching for IgM and IgG avidity by ELISA [13]. Frequencies of these aetiological agents analysed by age distribution have been published [14–17].

The patients were grouped into three distinct severity subgroups according to the World Health Organization (WHO) severity criteria for children aged 2 months and above available in the 2000 decade; patients with “non-severe” CAP had tachypnoea neither with chest indrawing nor with any danger signs, patients with “severe” CAP had chest indrawing or supraclavicular recession without any danger signs, and patients with “very severe” CAP presented any danger signs, which were inability to drink, convulsions, lethargy, stridor in a calm child, or central cyanosis [18]. Tachypnoea was defined as respiratory rate ≥50 breaths/min in children aged 2–11 months and respiratory rate ≥40 breaths/min in children aged 12–59 months [18]. Therefore, children aged under-

![Flow-chart of recruitment of children hospitalized with community-acquired pneumonia referred for aetiology investigation and grouped according to severity upon admission](https://example.com/image.png)

**Fig. 1** Flow-chart of recruitment of children hospitalized with community-acquired pneumonia referred for aetiology investigation and grouped according to severity upon admission
2 months, or without tachypnoea, or with missing respiratory rate, or missing danger signs were excluded. Severity classification was performed by a researcher blinded to the aetiological tests’ results, who had previously received training regarding the WHO severity criteria. Additionally, the patients were further grouped into two distinct severity subgroups according to the current WHO severity criteria published in 2013 [19]. According to these latter criteria, children with “non-severe” pneumonia have tachypnoea or chest wall indrawing, and children with “severe” pneumonia have central cyanosis, stridor in a calm child, inability to drink, lethargy, or convulsions, besides having tachypnoea or chest wall indrawing. That is, the subgroups “non-severe” and “severe” in the former criteria were grouped into the subgroup “non-severe” in the latter criteria; the subgroup labelled “very severe” in the former criteria was re-named “severe” in the latter criteria. Invasive disease was defined as positive blood culture (bacteraemia) or positive blood pneumococcal PCR.

For the purpose of analysis, the cases were classified as viral infection when only viral infection was detected, bacterial infection when bacterial infection was diagnosed irrespective of also viral infection having been detected; this last subgroup was split into two others: typical bacterial infection if infection by S. pneumoniae, H. influenzae, M. catarrhalis or S. aureus was found irrespective of other agents; atypical bacterial infection if infection by M. pneumoniae, C. trachomatis, C. pneumo-niae or S. negevensis was detected irrespective of viral infection.

Continuous variables showed non-parametric distribution and were presented as median [interquartile range (IQR)]. Categorical variables were compared using chi-square or Fisher’s exact test, as appropriate. A trend analysis for bacterial, typical bacterial, and pneumococcal

| Table 1 | Demographic and clinical characteristics of children with non-severe, severe or very severe community-acquired pneumonia |
| --- | --- |
| Characteristics | Severity by the World Health Organization 2000 criteria |
|  | Non-severe (n = 53) | Severe (n = 111) | Very severe (n = 17) |
| Age (months) | 23 (13–35) | 16 (9–26) | 18 (13–26) |
| Length of disease (days) | 7 (5–13) | 7 (4–11) | 8 (4–11) |
| Tachypnoea | 53 (100.0) | 97 (87.4) | 15 (88.2) |
| Chest indrawing | 0 | 109 (98.2) | 7 (41.2) |
| Supraclavicular recession | 0 | 4 (3.6) | 0 |
| Inability to drink | 0 | 0 | 17 (100.0) |

| Table 2 | Overall frequency of aetiological agents detected among 181 children hospitalized with community-acquired pneumonia |
| --- | --- |
| Aetiological agents | Frequency |
| S. pneumoniae | 39 (21.5) |
| positive blood culture | 8 (4.4) |
| positive blood PCR | 7 (3.9) |
| invasive infection | 13 (7.2) |
| increased paired IgG titres only | 26 (14.4) |
| H. influenzae | 13 (7.2) |
| M. pneumoniae | 11 (6.1) |
| C. trachomatis | 9 (5.0) |
| M. catarrhalis | 4 (2.2) |
| S. negevensis | 3 (1.7) |
| Rhinovirus | 39 (21.5) |
| RSV | 36 (19.9) |
| antigen in NPA and increased paired IgG titres | 17 (9.4) |
| antigen in NPA | 11 (6.1) |
| increased paired IgG titres | 8 (4.4) |
| Parainfluenza 1, 2, 3 | 35 (19.3) |
| antigen in NPA and increased paired IgG titres | 11 (6.0) |
| antigen in NPA | 2 (1.1) |
| increased paired IgG titres | 22 (12.2) |
| Influenza A, B | 15 (8.3) |
| antigen in NPA and increased paired IgG titres | 3 (1.65) |
| antigen in NPA | 3 (1.65) |
| increased paired IgG titres | 9 (5.0) |
| Human bocavirus | 17 (9.4) |
| low IgG avidity (<15) | 17 (9.4) |
| positive IgM | 16 (8.8) |
| qPCR in NPA >10E + 4/ml | 15 (8.3) |
| positive qPCR in serum | 4 (2.2) |
| IgG seroconversion | 3 (1.65) |
| increased paired IgG titres | 2 (1.1) |
| Adenovirus | 10 (5.5) |
| antigen in NPA and increased paired IgG titres | 3 (1.65) |
| antigen in NPA | 1 (0.55) |
| increased paired IgG titres | 6 (3.3) |
| Enterovirus | 10 (5.5) |
| Human metapneumovirus | 8 (4.4) |

Results in n (%) | 
| RSV | respiratory syncytial virus |
| NPA | nasopharyngeal aspirate |
| qPCR | quantitative polymerase chain reaction |
| *Invasive disease was defined as positive blood culture (bacteraemia) and/or positive blood PCR for pneumococcus |
| All three cases had IgM against S. negevensis detected |

aMedian (interquartile range) |
| bChildren with non-severe community-acquired pneumonia versus those with severe (p = 0.03) or versus those with severe and very severe CAP (p = 0.04) |
| cNo significant difference was found |
| dResults in n (%) |

**Nascimento-Carvalho et al. BMC Pediatrics (2016) 16:105**
infection across 3 different severity categories was performed using qui-squared test for trend. Continuous variables were assessed using Mann–Whitney U. Analysis was stratified by age. Multivariable logistic regression analysis by enter method assessed the potential impact of bacterial infection (predictor variable) on clinical severity upon admission (outcome variable) in an age adjusted model. Statistical tests were two-tailed, at significance level of 0.05. SPSS software (version 9.0, IBM, Armonk, New York) was used for analysis. Sample size was estimated considering a smaller frequency of bacterial infection in non-severe cases of 30 % and an expected frequency of bacterial infection in severe/very severe cases of 45 %. Thus, the sample size was estimated as 162 cases, considering a significance level of 0.05 (95 % Confidence Interval [95 % CI]) and power of 80 %. Exclusion criteria were chosen to address potential confounders. Blinding at severity classification was performed to address potential bias. Cases with any missing biological sample or data were excluded. Different data from the same research project have already been published. The novelty in this paper is the presentation of clinical characteristics which were used to group the cases in distinct severity categories, along with the analysis of the aetiological data across these distinct severity categories.

**Results**

Overall, 322 patients were evaluated, out of which 141 (43.8 %) were excluded due to different reasons (Fig. 1). Therefore, the study group comprised 181 patients (Fig. 1). There were no additional diagnoses as reasons for hospitalization. The overall median (IQR) age was 17 (10–27) months and there were 113 (62.4 %) boys. No patient had previously received either pneumococcal or influenza vaccines. On the contrary, 85.0 % had received

**Table 3** Comparison between frequencies of different aetiologies among children with non-severe or severe and/or very severe community-acquired pneumonia according to the World Health Organization 2000 criteria

| Aetiology                  | Overall frequency (n = 181) | Severity by the World Health Organization 2000 criteria |
|----------------------------|-----------------------------|--------------------------------------------------------|
|                            | Non-severe (n = 53)        | Severe or very severe (n = 128) | p  | Severe (n = 111) | p  | Very severe (n = 17) | p  |
| **Subgroups**              |                             |                             |    |                |    |                          |    |
| Detected                   | 156 (86)                    | 41 (77.4)                   | 115 (89.8) | 0.03  | 101 (91.0) | 0.017 | 14 (82.4) | 1  |
| Viral infection            | 84 (46.4)                   | 25 (47.2)                   | 59 (46.1) | 0.9   | 54 (48.6) | 0.9   | 5 (29.4) | 0.2 |
| Bacterial infection        | 72 (39.8)                   | 16 (30.2)                   | 56 (43.8) | 0.09  | 47 (42.3) | 0.1   | 9 (52.9) | 0.09|
| Typical bacterial infection| 54 (29.8)                   | 11 (20.8)                   | 43 (33.6) | 0.09  | 36 (32.4) | 0.1   | 7 (41.2) | 0.1 |
| Atypical bacterial infection| 18 (9.9)                    | 5 (9.4)                     | 13 (10.2) | 0.9   | 11 (9.9)  | 0.9   | 2 (11.8) | 1  |
| **Pathogens**              |                             |                             |    |                |    |                          |    |
| *S. pneumoniae*            | 39 (21.5)                   | 7 (13.2)                    | 32 (25.0) | 0.08  | 26 (23.4) | 0.1   | 6 (35.3) | 0.07|
| Positive blood culture     | 8 (4.4)                     | 3 (5.7)                     | 5 (3.9)  | 0.7   | 3 (2.7)   | 0.4   | 2 (11.8) | 0.6 |
| Positive blood PCR         | 7 (3.9)                     | 1 (1.9)                     | 6 (4.7)  | 0.7   | 5 (4.5)   | 0.7   | 1 (5.9)  | 0.4 |
| Invasive infection*        | 13 (7.2)                    | 3 (5.7)                     | 10 (7.8) | 0.8   | 8 (7.2)   | 1     | 2 (11.8) | 0.6 |
| *H. influenzae*            | 13 (7.2)                    | 4 (7.5)                     | 9 (7.0)  | 1     | 8 (7.2)   | 1     | 1 (5.9)  | 1  |
| *M. pneumoniae*            | 11 (6.1)                    | 6 (11.3)                    | 5 (3.9)  | 0.08  | 4 (3.6)   | 0.08  | 1 (5.9)  | 1  |
| *C. trachomatis*           | 9 (5.0)                     | 0                            | 9 (7.0)  | 0.06  | 9 (8.1)   | 0.03  | 0        | -   |
| *M. catarrhalis*           | 4 (2.2)                     | 0                            | 4 (3.1)  | 0.3   | 4 (3.6)   | 0.3   | 0        | -   |
| *S. rogens*                | 3 (1.7)                     | 0                            | 3 (2.3)  | 0.6   | 2 (1.8)   | 1     | 1 (5.9)  | 0.2 |
| Rhinovirus                 | 39 (21.5)                   | 13 (24.5)                   | 26 (20.3) | 0.5   | 26 (23.4) | 0.9   | 0        | 0.03|
| RSV                       | 36 (19.9)                   | 13 (24.5)                   | 23 (18.0) | 0.3   | 20 (18.0) | 0.3   | 3 (17.6) | 0.7 |
| Parainfluenza 1, 2, 3      | 35 (19.3)                   | 11 (20.8)                   | 24 (18.8) | 0.8   | 21 (18.9) | 0.8   | 3 (17.6) | 1  |
| Influenza A, B             | 15 (8.3)                    | 2 (3.8)                     | 13 (10.2) | 0.2   | 12 (10.8) | 0.2   | 1 (5.9)  | 1  |
| Human bocavirus            | 17 (9.4)                    | 3 (5.7)                     | 14 (10.9) | 0.4   | 14 (12.6) | 0.2   | 0        | -   |
| Adenovirus                 | 10 (5.5)                    | 2 (3.8)                     | 8 (6.3)  | 0.7   | 7 (6.3)   | 0.7   | 1 (5.9)  | 1  |
| Enterovirus                | 10 (5.5)                    | 1 (1.9)                     | 9 (7.0)  | 0.3   | 8 (7.2)   | 0.3   | 1 (5.9)  | 0.4 |
| Human metapneumovirus      | 8 (4.4)                     | 0                            | 8 (6.3)  | 0.1   | 7 (6.3)   | 0.1   | 1 (5.9)  | 0.2 |

Results in n (%)  
RSV respiratory syncytial virus  
*Invasive disease was defined as positive blood culture (bacteraemia) and/or positive blood PCR for pneumococcus
H. influenzae type b vaccine according to information retrieved from their vaccination cards. Cough (98.9 %), fever (96.7 %), and difficulty breathing (86.1 %) were the most frequent complaints. Antibiotic use in the previous 72 h (21.3 %) and asthma (23.9 %) were reported.

The patients were classified as non-severe \((n = 53; 29.3 \%)\), severe \((n = 111; 61.3 \%)\), or very severe \((n = 17; 9.4 \%)\) CAP (Fig. 1) in accordance with the WHO severity criteria available in the 2000 decade. Table 1 shows demographic and clinical characteristics of patients in each severity subgroup. Children with non-severe CAP were older than those with severe or severe plus very severe CAP. No significant differences were found among distinct severity subgroups in regard to duration of illness prior to hospitalization. Likewise, no difference was found when the frequency of asthma was compared between children with non-severe or severe plus very severe CAP \((23.1 \% vs. 24.2 \%, p = 0.9)\), as well as when the frequency of antibiotic use in the previous 72 h was compared \((13.7 \% vs. 24.4 \%, p = 0.1)\).

Overall, 156 \((86.2 \%)\) patients had detected aetiology. Viral infection \((n = 84; 46.4 \%)\), bacterial infection \((n = 26; 14.4 \%)\) and mixed viral-bacterial infection \((n = 46; 25.4 \%)\) were identified. Table 2 depicts the overall frequency of the found aetiological agents along with the frequency of the positive laboratory tests. No significant difference was found in the frequency of detected aetiology when children who did or did not receive antibiotic in the 72 h prior to hospital admission were compared \((86.8 \% vs. 86.4 \%, p = 0.9)\). Table 3 presents the comparison of different aetiologies among patients across distinct severity subgroups according to the WHO severity criteria in the 2000 decade. Aetiology was more likely to be determined in severe or very severe cases \((89.8 \%)\) compared to non-severe cases \((77.4 \%; p = 0.03)\). C. trachomatis infection was more frequent among severe \((8.1 \%)\) than non-severe \((0 \%)\) cases \((p = 0.03)\). Rhinovirus was significantly uncommon \((p = 0.03)\) among very severe cases \((0 \%)\) whereas 24.5 % of non-severe cases had rhinovirus found. Human metapneumovirus was detected only among severe \((63.3 \%)\) and very severe \((5.9 \%)\) patients. Pneumococcal infection increased across “non-severe” \((13.2 \%)\), “severe” \((23.4 \%)\), and “very severe” \((35.3 \%)\) cases (chi-squared test for trend \(p = 0.04)\). The frequency of bacterial and typical bacterial infection showed the same trend, being the statistical result borderline \((p = 0.06)\). Infection by C. pneumoniae or S. aureus was not detected. Table 4 compares the frequency of the different aetiologies among patients across distinct severity subgroups according to the WHO severity criteria published in the year 2013. In such analysis, rhinovirus was also significantly uncommon among severe cases in comparison with non-severe ones \((0 \% vs. 23.8 \%; p = 0.03)\).

### Table 4 Comparison between frequencies of different aetiologies among children with non-severe or severe and/or very severe community-acquired pneumonia according to the World Health Organization 2013 criteria

| Aetiology | Non-severe \((n = 164)\) | Severe \((n = 17)\) | \(p\) |
|-----------|--------------------------|-------------------|------|
| Subgroups |                          |                   |      |
| Detected  | 142 \((86.6)\)           | 14 \((82.4)\)     | 0.7  |
| Viral infection | 79 \((48.2)\)       | 5 \((29.4)\)      | 0.1  |
| Bacterial infection | 63 \((38.4)\)     | 9 \((52.9)\)      | 0.2  |
| Typical bacterial infection | 47 \((28.7)\)   | 7 \((41.2)\)      | 0.3  |
| Atypical bacterial infection | 16 \((9.8)\)    | 2 \((11.8)\)      | 0.7  |
| Pathogens |                          |                   |      |
| S. pneumoniae | 33 \((20.1)\)       | 6 \((35.3)\)      | 0.2  |
| Positive blood culture | 6 \((3.7)\)       | 2 \((11.8)\)      | 0.2  |
| Positive blood PCR | 6 \((3.7)\)        | 1 \((5.9)\)       | 0.5  |
| Invasive infection \(^3\) | 11 \((6.7)\)       | 2 \((11.8)\)      | 0.4  |
| H. influenzae | 12 \((7.3)\)        | 1 \((5.9)\)       | 1.0  |
| M. pneumoniae | 10 \((6.1)\)        | 1 \((5.9)\)       | 1.0  |
| C. trachomatis | 9 \((5.5)\)         | -                 | 1.0  |
| M. catarrhalis | 4 \((2.4)\)          | -                 | 1.0  |
| S. negevensis | 2 \((1.2)\)          | 1 \((5.9)\)       | 0.3  |
| Rhinovirus | 39 \((23.8)\)        | -                 | 0.03 |
| RSV | 33 \((20.1)\)        | 3 \((17.6)\)      | 1.0  |
| Parainfluenza 1, 2, 3 | 32 \((19.5)\)      | 3 \((17.6)\)      | 1.0  |
| Influenza A, B | 14 \((8.5)\)        | 1 \((5.9)\)       | 1.0  |
| Human bocavirus | 17 \((10.4)\)       | -                 | 0.4  |
| Adenovirus | 9 \((5.5)\)          | 1 \((5.9)\)       | 1.0  |
| Enterovirus | 9 \((5.5)\)          | 1 \((5.9)\)       | 1.0  |
| Human metapneumovirus | 7 \((4.3)\)        | 1 \((5.9)\)       | 0.6  |

Results in \(n \%(\)  

\(^3\)Invasive disease was defined as positive blood culture (bacteraemia) and/or positive blood PCR for pneumococcus

Because of the difference in age distribution in regard to different severity subgroups, we analysed age in regard to detected aetiology, pneumococcal, C. trachomatis, rhinovirus, or human metapneumovirus infection (Table 5). Age distribution was only different when children infected with human metapneumovirus were analysed: they were younger than those without it \((p = 0.046)\).

Among children with detected aetiology, by grouping cases with sole bacterial infection together with cases with mixed viral-bacterial infection in a subgroup labeled bacterial infection, in multivariable analysis controlled for age, bacterial infection did not affect severity upon admission, using the WHO severity criteria available either in the 2000 decade or in 2013 (Table 6).
Out of 156 patients with established aetiology, 91 (58.3 %) had infection caused by one pathogen and 65 (41.7 %) had infection caused by two or more pathogens. In the former group, 25 (27.5 %) cases had bacterial infection and 66 (72.5 %) had viral infection. Conversely, in the latter group, 46 (70.8 %) had viral-bacterial infection, and 1 (1.5 %) had bacterial-bacterial infection. Severe or very severe CAP was detected among 67 (73.6 %) patients with single infection, and among 48 (73.8 %) patients with co-infections (p = 1). Among patients with detected aetiology, after excluding cases with co-infection, the frequency of sole bacterial infection was different among children with non-severe (12.5 %), severe (29.3 %) or very severe (55.6 %) CAP cases (p = 0.04) (Table 7). Furthermore, by considering only the 91 cases with aetiology detected and without co-infection, sole bacterial infection was directly and independently associated with severity when the patients were grouped according to the WHO severity criteria available in the 2000 decade (Table 8). In this latter analysis, children with sole bacterial infection were compared with children with sole viral infection. The identified aetiological agents in the 25 cases with sole bacterial infection were *S. pneumoniae* (n = 12), *H. influenzae* (n = 4), *M. pneumoniae* (n = 4), *M. catarrhalis* (n = 2), *C. trachomatis* (n = 2), and *S. negevensis* (n = 1).

Cases with incomplete specimen collection (Fig. 1) were at random. In order to address systematic bias, the whole analysis was repeated with the inclusion of these cases and the results were the same (Additional file 1).

### Discussion

This study showed that respiratory viral infections were detected in a reasonable proportion of cases in each severity subgroup. The frequencies of these infections did not differ across the distinct severity categories. Notably, one third to half of the cases classified as severe CAP had respiratory viral infections (Tables 3 and 4). Human metapneumovirus was the only viral pathogen exclusively found in the severe or very severe categories (Table 3). However, the difference was not significant. Pneumococcal infection increased across “non-severe”, “severe”, and “very severe” cases (Table 3). Only after excluding co-infections, sole bacterial infection was significantly more frequent among children with severe or very severe CAP (Table 8). No difference was found in the frequency of invasive typical bacterial infection (Tables 3 and 4).

Viral CAP has been recognized as a frequent entity among children, with an estimated occurrence of 100 million cases annually of which one third presents viral-bacterial co-infection [20]. Molecular diagnostics have played a fundamental role in obtaining these findings [21]. Indeed, viruses currently account for the largest proportion of CAP in preschool children in both developed and developing countries [22]. However, the pathogenesis and clinical impact of viral lung infection is not well understood [23]. Interestingly, herein, human metapneumovirus infection was only identified among severe or very severe cases. Human metapneumovirus has been identified as a single pathogen in childhood infections.

#### Table 5 Comparison of age among children with or without specific aetiology

| Characteristics                        | Compared subgroups | p     |
|----------------------------------------|--------------------|-------|
| Detected aetiology                     | Yes (n = 156)      | No (n = 25) |
| Age (months)*                          | 17 (10–27)         | 19 (11–30)   | 0.5   |
| Pneumococcal infection                 | Yes (n = 39)       | No (n = 142) |
| Age (months)*                          | 21 (11–31)         | 17 (10–27)   | 0.8   |
| *C. trachomatis*                       | Yes (n = 9)        | No (n = 172) |
| Age (months)*                          | 15 (4–23)          | 21 (10–28)   | 0.2   |
| Rhinovirus infection                   | Yes (n = 39)       | No (n = 142) |
| Age (months)*                          | 17 (9–34)          | 18 (11–27)   | 0.7   |
| Human metapneumovirus infection        | Yes (n = 8)        | No (n = 173) |
| Age (months)*                          | 10 (5–18)          | 18 (11–28)   | 0.046 |

*Median (interquartile range)*

#### Table 6 Multivariable logistic regression analysis of bacterial infection and age (predictors) and severity (outcome) upon admission of hospitalized children with community-acquired pneumonia

| Predictors                  | Severity by the World Health Organization 2000 criteria | unadjOR (95 % CI) | p     | adjustOR (95 % CI) | p     |
|-----------------------------|-------------------------------------------------------|------------------|-------|--------------------|-------|
| Bacterial infection*        | Non-severe (n = 53)                                   | 16 (30.2)        | 56 (43.8) | 1.5 (0.7–3.1)       | 0.3   | 1.7 (0.8–3.5)       | 0.2   |
| Age (months)*               | Severe or very severe (n = 128)                       | 23 (13–35)       | 16 (9–26) | 0.8 (0.6–0.99)      | 0.04  | 0.7 (0.5–1.0)       | 0.07  |

| Severity by the World Health Organization 2013 criteria | unadjOR (95 % CI) | p     | adjustOR (95 % CI) | p     |
|-------------------------------------------------------|------------------|-------|--------------------|-------|
| Bacterial infection*        | Non-severe (n = 164) | 63 (38.4) | 9 (52.9) | 2.3 (0.7–7.1)       | 0.2   | 2.3 (0.7–7.3)       | 0.2   |
| Age (months)*               | Severe (n = 17)  | 17 (10–27)       | 18 (13–24) | 1.0 (0.6–1.6)       | 1.0   | 0.9 (0.6–1.6)       | 0.8   |

*Results in n (%)*

*Median (interquartile range)*
Table 7 Comparison between frequencies of sole bacterial and sole viral infection among 91 children hospitalized with community-acquired pneumonia and detected aetiology, after excluding cases with co-infection

| Aetiology                  | Severity by the World Health Organization 2000 criteria | unadjOR (95% CI) | p     | adjustOR (95% CI) | p     |
|----------------------------|--------------------------------------------------------|------------------|-------|-------------------|-------|
|                            | Non-severe (n = 24)  | Severe (n = 58)  | Very severe (n = 9) |       |                  |       |
| Sole bacterial infection    | 3 (12.5)         | 17 (29.3)        | 5 (55.6)            |       |                  |       |
| Sole viral infection        | 21 (87.5)        | 41 (70.7)        | 4 (44.4)            |       |                  |       |

Results in n (%)

*p = 0.04 for the frequency of sole bacterial infection across three distinct severity categories among patients with sole aetiological agent infection

Table 8 Multivariable logistic regression analysis of bacterial infection and age (predictors) and severity (outcome) upon admission of hospitalized children with community-acquired pneumonia with documented infection by only one pathogen

| Predictors                  | Severity by the World Health Organization 2000 criteria | unadjOR (95% CI) | p     | adjustOR (95% CI) | p     |
|-----------------------------|--------------------------------------------------------|------------------|-------|-------------------|-------|
|                            | Non-severe (n = 24)  | Severe or very severe (n = 67) |       |                  |       |
| Bacterial infection*        | 3 (12.5)         | 22 (32.8)        | 3.4 (0.9–12.7) | 0.07 | 4.4 (1.1–17.6)   | 0.04 |
| Age (months)*               | 19 (12–35)       | 17 (7–26)        | 0.8 (0.6–1.2)   | 0.3  | 0.7 (0.5–1.1)    | 0.1  |

Severity by the World Health Organization 2013 criteria

| Predictors                  | Severity (n = 82) | Severe (n = 9) |
|-----------------------------|-------------------|----------------|
| Bacterial infection*        | 20 (24.4)        | 5 (55.6)       |
| Age (months)*               | 18 (10–26)       | 19 (14–31)     |

*p = 0.04 for the frequency of sole bacterial infection across three distinct severity categories among patients with sole aetiological agent infection

Aetiology was more likely to be determined in severe or very severe cases (Table 3). Despite using an expanded range of diagnostic tests to search for each pathogen by different tools, aetiology was not detected in all cases. This finding may be attributable to unrecognized aetiological agents, or limitation of the employed methods, or both. Patients diagnosed as either severe or very severe cases were younger than those non-severe patients (Table 1). During the first three years of life whilst the immune system is maturing, particularly the production of IgG, the host is more vulnerable to infections [30]. Moreover, the first two years are often regarded as the most vulnerable period, especially for infections due to capsulated bacteria as pneumococcus and capsulated *H. influenzae*.

Our results must be viewed with caution. A higher number of cases would provide more precise results for comparing each pathogen’s frequencies. That is, low statistical power due to relatively small sample size is the main limitation of this study. Although a wide range of tests to investigate a big number of aetiological agents was performed, it was difficult to assign causality even if aetiology was known, especially when there were co-detections. Aetiology was established as probable because lung tissue was not studied, for ethical reasons. However, different techniques were used, sometimes searching for the same pathogen to strengthen each result. Besides searching for the pathogen (by blood culture or PCR or antigen detection) we also searched for the host’s...
response to the presence of the pathogen. Pneumococcal aetiology was assessed by blood culture, paired pneumococcal antibodies titres and buffy-coat PCR. This approach is better than culturing or performing PCR of respiratory samples as *S. pneumoniae* commonly colonizes children’s nasopharynx [31]. Antibody increase in paired serum samples due to acquisition of a new pneumococcal colonizing strain has been described to occur in <1 % to 3 % of the healthy children [32]. However, the final roles of pneumococcal serology and buffy-coat PCR are still open for discussion. The roles of non-capsulated *H. influenzae*, *M. catarrhalis*, and *S. negevensis* are less clear in the aetiology of childhood CAP. Likewise, serological diagnoses of Mycoplasma and Chlamydia infections are difficult. This approach may be acceptable, as no better approaches are currently available, particularly because Mycoplasma strains found in the upper respiratory samples can be detected by PCR without any relation to the current illness [33]. Additionally, the lack of pneumococcal and influenza vaccines resulted in difficulty to extend our findings to regions with high vaccine coverage. As such, in these regions, it is expected that the role of respiratory viruses is even more remarkable among children hospitalized with CAP, whilst pneumococcal infection is supposedly less frequent. In a recent study on CAP among 2,222 U.S. hospitalized children, viral (66 %), bacterial (8 %), or viral-bacterial (7 %) infections were reported [34]. However, the relative positivity rates between non-pneumococcal and non-influenza pathogens reported herein are still of interest. Additionally, it is important to note that severity was assessed on the basis of clinical findings present upon admission and not inferred from the evolution of the patients, as well as, severity was measured by using standardized protocols by a blinded investigator.

The WHO changed the severity CAP criteria in 2013 in order to make feasible the treatment at home of cases previously labeled as severe [19]. Several differences in the aetiologies frequencies were found when we used the WHO severity criteria available in the 2000 decade [18], but not all these differences were found when we used the WHO severity criteria published in 2013 [19] (Tables 3, 4 and 8). This finding raises the question about possible true differences among the subgroups formed by using the 2000 WHO severity criteria, as WHO changed these criteria to facilitate treatment logistic.

**Conclusions**

Respiratory viral infections were detected in a reasonable proportion of cases in each severity subgroup. A high proportion of patients with viral detections supports the need for more antiviral medicines and vaccines. Bacterial infection, particularly pneumococcal infection, was more likely among severe/very severe cases. This finding supports the use of empiric antibiotics to treat these patients, as it has been done in clinical practice.

---

**Additional file**

**Additional file 1:** Dataset of children hospitalized with community-acquired pneumonia in distinct severity categories with aetiology results. Demographic, clinical, and aetiology data on children hospitalized with community-acquired pneumonia. (XLS 219 kb)

**Abbreviations**

95 % CI, 95 % confidence interval; CAP, community-acquired pneumonia; ELISA, enzyme immune assay; IQR, interquartile range; MIF, microinmunofluorescence; NPA, nasopharyngeal aspirate; PCR, polymerase chain reaction; RSV, respiratory syncytial virus; WHO, World Health Organization.

**Acknowledgements**

Not applicable.

**Funding**

This study was supported by the Bahia State Agency for Research Funding (FAPESB) [grant number 52/2004] and the Brazilian Council for Scientific and Technological Development (CNPq) [grant number 303551/2011-9]. CMN-C is an investigator at CNPq. The funding agencies had no role in the design of the study and collection, analysis and interpretation of data and in writing the manuscript.

**Availability of data and materials**

The dataset on which the conclusions of this manuscript rely is available as the Additional file 1 of this manuscript.

**Authors’ contributions**

CMN-C designed the study and conducted the collection of data. OR contributed to the study design, data analysis and interpretation. ACN-C analysed the data and drafted the manuscript. CMN-C and OR proofread the manuscript. All authors read and approved the final manuscript.

**Authors’ information**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

This study was conducted in accordance with The Code of the World Medical Association for experiments involving humans. It was approved by the Ethics Committee of the Federal University of Bahia and written informed consent was obtained before recruitment.

**Author details**

1Bahiana School of Medicine, Bahiana Foundation for Science Development, Salvador, Bahia, Brazil. 2Department of Paediatrics, Turku University and University Hospital, Turku, Finland. 3Department of Paediatrics, Federal University of Bahia School of Medicine, Salvador, Bahia, Brazil.

Received: 6 February 2016 Accepted: 15 July 2016
Published online: 22 July 2016

**References**

1. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381:1405–16.

2. Shann F. Etiology of severe pneumonia in children in developing countries. Pediatr Infect Dis. 1986;5:247–52.
3. Vuon-Holopainen E, Peltola H. Reappraisal of lung tap: review of an old method for better etiologic diagnosis of childhood pneumonia. Clin Infect Dis. 2001;32:715–26.

4. Gilani Z, Kwong YD, Levine OS, Deloria-Knoll M, Scott JA, O'Brien KL, et al. A literature review and survey of childhood pneumonia etiology studies: 2000-2010. Clin Infect Dis. 2012;54 Suppl 2:102–8.

5. Johansson N, Kälín M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010;50:202–9.

6. Howie SR, Morris GA, Tokarz R, Ebruke BE, Machuka EM, Ideh RC, et al. Etiology of severe childhood pneumonia in The Gambia West Africa determined by conventional and molecular microbiological analyses of lung and pleural aspirate samples. Clin Infect Dis. 2014;59:682–5.

7. Nohynek H, Eskola J, Kleemola M, Jalonen E, Saikku P, Leinonen M. Bacterial antibody assays in the diagnosis of acute lower respiratory tract infection in children. Pediatr Infect Dis J. 1995;14:478–84.

8. Saukkoriipi A, Palmu A, Klipi T, Leinonen M. Real-time quantitative PCR for the detection of Streptococcus pneumoniae in the middle ear fluid of children with acute otitis media. Mol Cell Probes. 2002;16:385–90.

9. Atkinson TP, Waites KB. Mycoplasma pneumoniae infections in childhood. Pediatr Infect Dis J. 2014;33:92–4.

10. Morré SA, Munk C, Persson K, Krüger-Kjær S, van Dijk R, Meijer CJ, et al. Comparison of three commercially available peptide-based immunoglobulin G (IgG) and IgA assays to microimmunofluorescence assay for detection of Chlamydia trachomatis antibodies. J Clin Microbiol. 2002;40:84–7.

11. Yamaguchi T, Yamazaki T, Inoue M, Mashida C, Kawagoe K, Ogawa M, et al. Prevalence of antibodies against Simkania negevensis in a healthy Japanese population determined by the microimmunofluorescence test. FEMS Immunol Med Microbiol. 2005;43:21–7.

12. Mákelä MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol. 1998;36:339–42.

13. Korppi M, Jartti T, Hedman K, Söderlund-Venermo M. Serologic diagnosis of human bocavirus infection in children. Pediatr Infect Dis J. 2010;29:387.

14. Nascimento-Carvalho CM, Ribeiro CT, Cardoso MR, Barral A, Araújo-Neto CA, Oliveira JR, et al. The role of respiratory viral infections among children hospitalized for community-acquired pneumonia in a developing country. Pediatr Infect Dis J. 2008;27:939–41.

15. Nascimento-Carvalho CM, Cardoso MR, Paldaniani M, Barral A, Araújo-Neto CA, Saukkoriipi A, et al. Simkania negevensis infection among Brazilian children hospitalized with community-acquired pneumonia. J Infect. 2009;58:250–3.

16. Nascimento-Carvalho CM, Cardoso MR, Ruuskanen O, Lappalainen M. Sole infection by human metapneumovirus among children with radiographically diagnosed community-acquired pneumonia in a tropical region. Influenza Other Respir Viruses. 2015;9:285–7.

17. Nascimento-Carvalho CM, Cardoso MR, Merliuaco M, Kemppainen K, Kantola K, Ruuskanen O, et al. Human bocavirus infection diagnosed serologically among children admitted to hospital with community-acquired pneumonia in a tropical region. J Med Virol. 2012;84:253–8.

18. World Health Organization. Management of the child with a serious infection or severe malnutrition: guidelines for care at the first-referral level in developing countries. 2000. http://apps.who.int/iris/bitstream/10665/42335/1/WHO_FCH_CAH_00.1.pdf. Page 20. Accessed 2 May 2013.

19. World Health Organization. Pocket book of hospital care for children. Guidelines for the management of common childhood illnesses. 2nd ed. 2013. http://www.who.int/maternal_child_adolescent/documents/child_hospital_care/en/index.html. Page 81. Accessed 7 June 2013.

20. Ruuskanen O, Lahiri E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011;377:1264–75.

21. Nolte FS. Molecular diagnostics for detection of bacterial and viral pathogens in community-acquired pneumonia. Clin Infect Dis. 2008;47 Suppl 3:123–6.

22. Mameli C, Zuccotti GV. The impact of viral infections in children with community-acquired pneumonia. Curr Infect Dis Rep. 2013;15:197–202.

23. Ruuskanen O, Janvinen A. What is the real role of respiratory viruses in severe community-acquired pneumonia? Clin Infect Dis. 2014;59:71–3.

24. Woods CR, Bryant KA. Viral infections in children with community-acquired pneumonia. Curr Infect Dis Rep. 2013;15:177–83.

25. Wolf DG, Greenberg D, Shemer-Avim Y, Givon-Lavi N, Bar-Ziv J, Dagan R. Association of human metapneumovirus with radiologically diagnosed community-acquired alveolar pneumonia in young children. J Pediatr. 2010;156:115–20.

26. Principi N, Esposito S. Paediatric human metapneumovirus infection: epidemiology, prevention and therapy. J Clin Virol. 2014;59:141–7.

27. Rudan I, O'Brien KL, Nair H, Liu L, Theodoratou E, Qazi S, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health. 2013;3:510401.

28. Lin SH, Lai CC, Tan CK, Liao WH, Hsieh PR. Outcomes of hospitalized patients with bacterial and non-bacterial community-acquired pneumonia caused by Streptococcus pneumoniae. Epidemiol Infect. 2011;139:1307–16.

29. Bordón J, Peyani P, Brodk GN, Blai F, Rello J, File T, et al. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired-Pneumonia Organization (CAPO) International Cohort study. Chest. 2008;133:618–24.

30. Ishimine P. Fever without source in children 0 to 36 months of age. Pediatr Clin North Am. 2006;53:167–94.

31. Bogaert D, Sluiter M, Tomon NL, Mitchell TJ, Goessens WH, Clarke SC, et al. Dynamics of pneumococcal colonization in healthy Dutch children. Microbiology. 2006;152:377–85.

32. Korppi M, Leinonen M, Ruuskanen O. Pneumococcal serology in children's respiratory infections. Eur J Clin Microbiol Infect Dis. 2008;27:167–75.

33. Spueses EB, Fraaij PL, Visser EG, Hoogenboezem T, Hop WC, van Adrichem LN, et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med. 2013;10:e1001444.

34. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372:835–45.